Radiopaque and X‐ray‐Responsive Nanomedicine for Preventive Therapy of Radiation‐Induced Heart Disease
Source abstract
Abstract
Abstract Radiation‐induced heart disease (RIHD) is a common radiotherapy complication. Reducing radiation exposure and post‐irradiation antioxidant therapy are promising approaches. Here, a liquid metal‐based core–shell nanomedicine (LMN) composed of a gallium core and a multifunctional polymeric shell with radiopaque, X‐ray shielding, and X‐ray‐responsive antioxidation properties for preventive therapy of RIHD is developed. The liquid metal provides radiopaque properties to enhance X‐ray and computed tomography imaging and attenuate radiation to prevent primary myocardial damage. Under X‐ray radiation, cleavage of the diselenide bond on the polymeric shell results in the release of LMN and controlled antioxidation. In vitro and in vivo experiments have demonstrated that LMN significantly reduces myocardial injury and impaired cardiac function, stabilizes mitochondrial function, and inhibits myocardial fibrosis. This nanomedicine with radiographic contrast, radiation shielding, and responsive features provides a new strategy for the prevention of radiation‐related diseases.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Polymer Nanocomposite Synthesis and Irradiation · Radiation Effects in Electronics · Radiation Therapy and Dosimetry
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Rehabilitation Medicine the Second Affiliated Hospital of Nanchang University Nanchang University Nanchang Jiangxi 330006 P. R. China
The Institute of Translational Medicine the Second Affiliated Hospital of Nanchang University Nanchang University Nanchang Jiangxi 330006 P. R. China
Funding
National Key Research and Development Program of China · National Natural Science Foundation of China · Natural Science Foundation of Jiangxi Province · Youth Science Foundation of Jiangxi Province
References (38)
Show source-provided references
1. 10.7150/ijbs.3546010.7150/ijbs.35460 ↗
2. 10.3389/fcvm.2020.0001610.3389/fcvm.2020.00016 ↗
3. 10.3389/fcvm.2022.86418810.3389/fcvm.2022.864188 ↗
4. 10.1155/2021/582693210.1155/2021/5826932 ↗
5. 10.4149/BLL_2018_01110.4149/BLL_2018_011 ↗
6. 10.1093/annonc/mds29310.1093/annonc/mds293 ↗
7. 10.3857/roj.2021.0076610.3857/roj.2021.00766 ↗
8. 10.1016/j.ijrobp.2007.12.05810.1016/j.ijrobp.2007.12.058 ↗
9. 10.1002/anie.20220083010.1002/anie.202200830 ↗
10. 10.1002/adma.20210578310.1002/adma.202105783 ↗
11. 10.1002/adfm.20211316810.1002/adfm.202113168 ↗
12. 10.1016/j.pnucene.2021.10369610.1016/j.pnucene.2021.103696 ↗
13. 10.1007/s10534-019-00212-510.1007/s10534-019-00212-5 ↗
14. 10.1159/00050297910.1159/000502979 ↗
15. 10.1080/14740338.2019.166610410.1080/14740338.2019.1666104 ↗
16. 10.1371/journal.pone.009596810.1371/journal.pone.0095968 ↗
17. 10.3390/ma1506214510.3390/ma15062145 ↗
18. 10.1016/j.jelechem.2013.08.00810.1016/j.jelechem.2013.08.008 ↗
19. 10.1002/smll.20190264210.1002/smll.201902642 ↗
20. 10.1016/j.ijpharm.2013.06.01910.1016/j.ijpharm.2013.06.019 ↗
21. 10.1021/acsami.8b0232010.1021/acsami.8b02320 ↗
22. 10.1002/adma.20200438510.1002/adma.202004385 ↗
23. 10.1021/acsnano.8b0402210.1021/acsnano.8b04022 ↗
24. 10.1200/JCO.2015.63.444410.1200/JCO.2015.63.4444 ↗
25. 10.1007/s00018-020-03479-x10.1007/s00018-020-03479-x ↗
26. 10.3390/antiox803007210.3390/antiox8030072 ↗
27. 10.1007/s00204-015-1579-510.1007/s00204-015-1579-5 ↗
28. 10.1186/s12933-020-00998-610.1186/s12933-020-00998-6 ↗
29. 10.1038/s41580-019-0173-810.1038/s41580-019-0173-8 ↗
30. 10.1038/nrcardio.2017.5710.1038/nrcardio.2017.57 ↗
31. 10.1155/2019/427865810.1155/2019/4278658 ↗
32. 10.1016/j.redox.2015.09.00910.1016/j.redox.2015.09.009 ↗
33. 10.1161/ATVBAHA.108.18161010.1161/ATVBAHA.108.181610 ↗
34. 10.7717/peerj.1279710.7717/peerj.12797 ↗
35. 10.1002/adhm.20170011410.1002/adhm.201700114 ↗
36. 10.1111/jcmm.1547910.1111/jcmm.15479 ↗
37. Heidenreich P. A. · Circulation · 2022 · 145
38. 10.1093/eurheartj/ehw12810.1093/eurheartj/ehw128 ↗